Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 285986-88-1 Chemical Structure| 285986-88-1

Structure of CCG-1423
CAS No.: 285986-88-1

Chemical Structure| 285986-88-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CCG-1423 inhibits RhoA/C-mediated gene transcription and the invasion of rho-overexpressing cell lines.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CCG-1423

CAS No. :285986-88-1
Formula : C18H13ClF6N2O3
M.W : 454.75
SMILES Code : O=C(NOC(C)C(NC1=CC=C(Cl)C=C1)=O)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2
MDL No. :MFCD01566719
InChI Key :DSMXVSGJIDFLKP-UHFFFAOYSA-N
Pubchem ID :2726015

Safety of CCG-1423

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H315-H319-H228
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Isoform Comparison

Biological Activity

Target
  • Rho-subclass

In Vitro:

Cell Line
Concentration Treated Time Description References
AGS 7.5 μM CCG-1423 effectively inhibited GC cells' invasion and MYH9 expression Theranostics. 2017 Aug 2;7(13):3338-3353.
MGC 80-3 7.5 μM CCG-1423 effectively inhibited GC cells' invasion and MYH9 expression Theranostics. 2017 Aug 2;7(13):3338-3353.
vascular smooth muscle cells 5 μM or 20 μM 24 h CCG-1423 inhibited H2O2-induced FOXM1 expression Redox Biol. 2023 Feb;59:102586.
vascular smooth muscle cells 5 μM or 20 μM 24 h CCG-1423 inhibited PDGF-induced FOXM1 expression Redox Biol. 2023 Feb;59:102586.
HEK293T cells 5 μM 4 h CCG-1423 significantly inhibited MICAL-2-induced SRF/MRTF-A reporter gene expression, reducing luciferase expression by 75%. Cell. 2014 Jan 30;156(3):563-76.
L6 myoblasts 1 μM CCG-1423 reversed palmitate-induced MKL1 nuclear localization, resulting in predominant localization of MKL1 to the cytosol. J Clin Invest. 2011 Mar;121(3):918-29.
L6 myotubes 1 μM 16 h CCG-1423 increased both basal and insulin-stimulated glucose uptake and blocked SRF activity by inhibiting MKL1 nuclear localization. J Clin Invest. 2011 Mar;121(3):918-29.
HmVEC 0.5, 1, 2.5, 5 µM 24 h CCG-1423 significantly inhibited the cord-forming ability of HmVEC, with 45% inhibition at 1 µM, 80% inhibition at 2.5 µM, and almost complete inhibition at 5 µM. Angiogenesis. 2017 Nov;20(4):663-672.
A10 VSMCs 0.1 μM 30 min CCG-1423 partially blocked the inhibitory effect of MYDGF on PDGF-BB-induced phenotypic switching in A10 VSMCs Acta Pharmacol Sin. 2024 Jan;45(1):98-111.
RH30 cells 10 µM 5 h CCG-1423 and PAX3-FOXO1 showed a significant synergistic effect in suppressing ACTA1 reporter activity. Cell Biosci. 2021 Jan 28;11(1):25.
TW03 80.55 μM 24 h CCG-1423 reversed the migration and invasion abilities of Nogo-B and NgR3, and downregulated the expression of N-Cadherin and MRTFA Cell Death Dis. 2022 Jan 24;13(1):76.
HK1 30.19 μM 24 h CCG-1423 reversed the migration and invasion abilities of Nogo-B and NgR3, and downregulated the expression of N-Cadherin and MRTFA Cell Death Dis. 2022 Jan 24;13(1):76.
RH30 cells 10 µM 5 h Observed significant synergistic effect between PAX3-FOXO1 and CCG-1423 to suppress ACTA1 reporter activity Cell Biosci. 2021 Jan 28;11(1):25.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice HFD-induced obese mice Intraperitoneal 0.15 mg/kg Once daily for 2 weeks CCG-1423 improved glucose tolerance in HFD-fed mice and decreased expression of SRF targets in skeletal muscle. J Clin Invest. 2011 Mar;121(3):918-29.
Nude mice Orthotopic-transplant nude-mouse models of GC Intraperitoneally 0.15 mg/kg Every 2 weeks for 2 weeks The tumor volumes of CCG-1423-treated group were smaller than the control group, and the metastatic nodules were also significantly less in CCG-1423-treated group Theranostics. 2017 Aug 2;7(13):3338-3353.
Mice Carotid artery ligation model Intraperitoneal injection 1 mg/kg Daily for 4 weeks CCG-1423 inhibited neointima formation after carotid artery ligation Redox Biol. 2023 Feb;59:102586.
Zebrafish Tg(kdrl:gfp)la116 zebrafish embryos Directly added to water 0.5, 1 µM 22 hours CCG-1423 at 1 μM significantly inhibited angiogenesis in zebrafish embryos, marked by reduced ISV (intersegmental vessel) formation and incomplete extension. Angiogenesis. 2017 Nov;20(4):663-672.
Mice CAP2-CKO mouse model Intraperitoneal injection 0.15 mg/kg Once daily for 21 days To evaluate the effect of CCG-1423-8u on cardiac function and survival in CAP2-CKO mice, results showed that CCG-1423-8u significantly extended survival and improved cardiac function JCI Insight. 2019 Mar 21;4(6):e124629

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.20mL

0.44mL

0.22mL

11.00mL

2.20mL

1.10mL

21.99mL

4.40mL

2.20mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories